Search results for "progress"

showing 10 items of 1620 documents

Parry Romberg Syndrome with localized scleroderma: a case report

2014

Parry Romberg syndrome(PRS) is a rare acquired poorly understood neurocutaneous syndrome of unknown etiology characterized by slow progressive atrophic changes commonly affecting one half of the face. The exact incidence and etiology towards the syndrome remains unclear. Apart from the multifactorial etiology proposed, the possible primary cause is mainly attributed to the cerebral disturbance of the fat metabolism. The syndrome overlaps with “en coup de sabre” morphea, with an ill defined relationship existing between the two. Parry Romberg Syndrome is an invalidating lesion that may be associated with different neurological, cutaneous, ocular, dental and autoimmune abnormalities. This rep…

medicine.medical_specialtyPathologyOral Medicine and Pathologybusiness.industryCase ReportParry–Romberg syndromeOdontologíamedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludProgressive Hemifacial AtrophyLesionstomatognathic diseasesFemale patientUNESCO::CIENCIAS MÉDICASmedicineEtiologyEn coup de sabremedicine.symptombusinessLocalized SclerodermaGeneral DentistryMorphea
researchProduct

Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection

2015

Abstract Aggressive B-cell Lymphomas are the second most frequent AIDS-defining cancers. Few studies have compared the molecular characteristics of aggressive B-cell lymphomas in patients with and without HIV-infection; and to our knowledge, there are no reports comparing the incidence of gene rearrangements between the two groups and their impact on outcome in series treated with RCHOP. We retrospectively studied two series of patients with (N=32) and without HIV-infection (N=43) with diffuse large B-cell lymphomas (DLBCL) NOS (75% and 70%, respectively), T-rich DLCBL (13% and 5%), transformed DLBCL (3% and 14%) and double-hit (DH) DLCBL (9% and 11%) [defined by translocations affecting MY…

medicine.medical_specialtyPathologybusiness.industryIncidence (epidemiology)ImmunologyFollicular lymphomaCell BiologyHematologyCHOPmedicine.diseaseBiochemistryGastroenterologyLymphomaExact testInternational Prognostic IndexInternal medicinemedicineProgression-free survivalbusinessDiffuse large B-cell lymphomaBlood
researchProduct

Spinal Intradural Intramedullary Dissemination in the Absence of Intracranial Relapse of a Previously Radically Treated Temporal Lobe Glioblastoma Mu…

2017

Intracranial glioblastoma multiforme (GBM) constitutes the most frequent and unfortunately aggressive primary central nervous system malignancy. Despite the high tendency of these tumors to show local relapse within the brain after primary therapy, dissemination into the spinal axis is an infrequent event. If spinal metastases occur they are leptomeningeal in the vast majority of cases and always in the context of intracranial progressive disease. Spinal intramedullary metastases of intracranial GBM have rarely been described to date. We report the unique case of a young woman with subacute progressive paraparesis due to spinal intramedullary metastases of a temporal lobe GBM despite the re…

medicine.medical_specialtyPathologymedicine.medical_treatmentCentral nervous systemSpinal intradural intramedullary disseminationContext (language use)Case ReportMalignancylcsh:RC254-282Temporal lobelaw.inventionIntramedullary rod03 medical and health sciences0302 clinical medicinelawmedicineChemotherapybusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.anatomical_structureOncology030220 oncology & carcinogenesisTemporal lobe glioblastoma multiformeRadiologybusiness030217 neurology & neurosurgeryProgressive diseaseGlioblastomaCase Reports in Oncology
researchProduct

Molecular Progression in Unusual Recurrent Non-Pediatric Intracranial Clear Cell Meningioma

2017

We report a case of a recurrent clear cell meningioma (CCM) in the frontal lobe of the brain of a 67-year-old man. The patient developed three recurrences: at 3, 10, and 12 years after his initial surgery. Histopathology observations revealed a grade 2 CCM with positivity for vimentin and epithelial membrane antigen. Expression of E-cadherin was positive only in the primary tumour and in the first available recurrence. Fluorescence in situ hybridization analyses demonstrated 1p and 14q deletions within the last recurrence. Multiplex ligation-dependent probe amplification studies revealed a heterozygous partial NF2 gene deletion, which progressed to total loss in the last recurrence. The las…

medicine.medical_specialtyPathologyrecurrenceCase ReportVimentin03 medical and health sciences0302 clinical medicineCDKN2ACDKN2BmedicineClear Cell MeningiomaNeoplasmgeneticstumour suppressor genesbiologymedicine.diagnostic_testbusiness.industryintracranial diseaseClear cell meningiomamedicine.diseaseFrontal lobemolecular progressionNF2030220 oncology & carcinogenesisbiology.proteinHistopathologynon-pediatric diseasebusiness030217 neurology & neurosurgeryFluorescence in situ hybridizationCurrent Oncology
researchProduct

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

2011

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

medicine.medical_specialtyPediatricspml; iris; multiple sclerosis; natalizumabMultiple SclerosisNeurologypmlMEDLINEProgressive MultifocalDermatologyRelapsing-RemittingAntibodies Monoclonal HumanizedAntibodiesLeukoencephalopathyMultiple Sclerosis Relapsing-RemittingNatalizumabLeukoencephalopathyMonoclonalmedicineHumansAdverse effectAntibodies; Monoclonal; Humanized Antibodies; therapeutic use Humans Leukoencephalopathy; Progressive Multifocal; chemically induced Multiple Sclerosis; Relapsing-Remitting; drug therapyHumanizedMultiple sclerosis Natalizumab PML IRISirisbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisLeukoencephalopathy Progressive MultifocalAntibodies MonoclonalGeneral Medicinemedicine.diseasedrug therapyPsychiatry and Mental healththerapeutic usechemically inducednatalizumab multiple sclerosis treatment guidelinesPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusinessmedicine.drug
researchProduct

Imaging appearance of treated hepatocellular carcinoma

2013

Surgical resection and imaging guided treatments play a crucial role in the management of hepatocellular carcinoma (HCC). Although the primary end point of treatment of HCC is survival, radiological response could be a surrogate end point of survival, and has a key role in HCC decision-making process. However, radiological assessment of HCC treatment efficacy is often controversial. There are few doubts on the evaluation of surgical resection; in fact, all known tumor sites should be removed. However, an unenhancing partial linear peripheral halo, in most cases, surrounding a fluid collection reducing in size during follow-up is demonstrated in successfully resected tumor with bipolar radio…

medicine.medical_specialtyPercutaneousHepatologySurrogate endpointbusiness.industryRadiofrequency ablationmedicine.medical_treatmentHepatocellular carcinoma Imaging TreatmentMinireviewsmedicine.diseaseAblationSurgerylaw.inventionTumor progressionlawHepatocellular carcinomamedicineClinical endpointPercutaneous ethanol injectionbusiness
researchProduct

Oral capecitabine and Vinorelbine in Metastatic Breast Cancer. A Retrospective Analysis of Tolerability and Activity

2012

ABSTRACT Background The purpose of this study was to retrospectively analyze toxicity profile and activity of an all-oral combination schedule of Capecitabine (Cape) and Vinorelbine (VNR) in metastatic breast cancer (MBC) patients (pts). Methods All pts treated had a histological confirmed diagnosis of breast cancer (BC). Each 3-week cycle of treatment consisted of 500 mg/m2 cape twice daily (2 weeks on, 1 week off), and 60 mg/m2 VNR on days 1 and 8. Results From June'07 to December'11 we analyzed 77 MBC pts. Median age was 52 years (range 34-73). 58 pts (75,3%) had a performance status (PS) ECOG 0; 13 pts (16,8%) PS1, 6 pts (7,8%) PS2. 5 pts (6,5%) had metastatic disease at time of diagnos…

medicine.medical_specialtyPerformance statusbusiness.industrymacromolecular substancesHematologyNeutropeniamedicine.diseaseVinorelbineMetastatic breast cancerGastroenterologycarbohydrates (lipids)Capecitabinestomatognathic diseasesRegimenBreast cancerOncologyInternal medicineotorhinolaryngologic diseasesmedicinebacteriaProgression-free survivalbusinessmedicine.drugAnnals of Oncology
researchProduct

Clinical Efficacy of Laquinimod for the Treatment of Multiple Sclerosis; Pooled Analyses from the ALLEGRO and BRAVO Phase III Trials (S01.007)

2012

Objective: The current report provides detail on pooled analyses assessing the effect of laquinimod on relapse, disability, and brain atrophy measures from the recently completed phase III trials ALLEGRO and BRAVO. Background Laquinimod is an oral, CNS acting immunomodulator in development for the treatment of multiple sclerosis. Its impact on disability progression and brain atrophy, two indices of longterm outcome for patients with multiple sclerosis (MS) are being studied in its phase III trials. Design/Methods: MS patients (N=2437) were randomized to laquinimod (n=984) or placebo (n = 1006). In both trials, patients underwent neurological examinations including the Expanded Disability S…

medicine.medical_specialtyPhase iii trialsbusiness.industryRelapse ratePharmacologyClinical trialSafety profilechemistry.chemical_compoundchemistryFamily medicineMedicinemedia_common.cataloged_instanceDisability progressionNeurology (clinical)Clinical efficacyEuropean unionbusinessLaquinimodmedia_commonNeurology
researchProduct

Health-Related Quality of Life Is Severely Affected in Primary Orthostatic Tremor

2018

International audience; Background: Primary orthostatic tremor (POT) is a movement disorder characterized by unsteadiness upon standing still due to a tremor affecting the legs. It is a gradually progressive condition with limited treatment options. Impairments in health-related quality of life (HQoL) seem to far exceed the physical disability associated with the condition.Methods: A multi-center, mixed-methodology study was undertaken to investigate 40 consecutive patients presenting with POT to four movement disorder centers in France. HQoL was investigated using eight quantitative scales and a qualitative study which employed semi-structured interviews. Qualitative data were analyzed wit…

medicine.medical_specialtyPhysical disabilityQualitative propertyprogressiveFear of fallinglcsh:RC346-429Grounded theory03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Physical medicine and rehabilitationMedicine030212 general & internal medicinelcsh:Neurology. Diseases of the nervous systemOriginal Researchbusiness.industryMultimethodology3. Good healthprimary orthostatic tremorhealth-related quality of lifeNeurology[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC][SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]movement disorderNeurology (clinical)Thematic analysismedicine.symptombusinessmixed-method methodology030217 neurology & neurosurgeryNeuroscienceQualitative research
researchProduct

Sequentielle transarterielle Chemoembolisation (TACE) des hepatozellulären Karzinoms (HCC) - Erfahrungsbericht eines einzelnen Zentrums über 5 Jahre

2007

PURPOSE: To analyze the course of disease of patients treated with sequential TACE and to evaluate the dependent and independent prognostic factors for patient survival using the Cox Proportional Hazard Model. MATERIALS AND METHODS: 94 patients palliatively treated with TACE. Patients were selected if they had been treated at least 3 times. The TACE procedure was carried out at 8-week intervals using a suspension consisting of a fixed dosage of Mitomycin C (10 mg) and 10 ml Lipiodol. Follow-up investigations included contrast-enhanced multislice CT before and after TACE and assessment of the laboratory test results (i. e., blood count, liver enzymes, and coagulation). RESULTS: In 66.7 % of …

medicine.medical_specialtyProportional hazards modelbusiness.industrymedicine.diseaseSingle CenterGastroenterologyPortal vein thrombosisTumor progressionInternal medicineHepatocellular carcinomaAscitesmedicineLipiodolRadiology Nuclear Medicine and imagingRadiologyLiver functionmedicine.symptombusinessmedicine.drugRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct